本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Clearmind Medicine, Inc.

0.2800
-0.0052-1.82%
成交量:992.46万
成交额:268.48万
市值:153.06万
市盈率:-0.33
高:0.2948
开:0.2600
低:0.2500
收:0.2852
52周最高:2.18
52周最低:0.2400
股本:546.64万
流通股本:531.86万
量比:0.78
换手率:186.60%
股息:- -
股息率:- -
每股收益(TTM):-0.8560
每股收益(LYR):-1.6950
净资产收益率:-178.64%
总资产收益率:-59.68%
市净率:1.44
市盈率(LYR):-0.17

数据加载中...

2025/09/19

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2025/01/22

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/12/09

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/11/15

超过5%披露

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
2024/03/27

[修订]年度报告

Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
2024/03/19

SEC问询函

Form CORRESP - Correspondence
2024/03/18

[修订]年度报告

Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
2024/02/14

SEC问询函

Form CORRESP - Correspondence
2024/02/14

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/07

招股说明书

Form F-1 - Registration statement for certain foreign private issuers
2024/02/06

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/01/29

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/01/22

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/12/27

SEC问询函

Form CORRESP - Correspondence
2023/09/14

[修订]招股说明书

Form F-1/A - Registration statement for certain foreign private issuers: [Amend]
2023/09/13

SEC问询函

Form CORRESP - Correspondence
2023/09/06

SEC问询函

Form CORRESP - Correspondence
2023/09/05

SEC问询函

Form CORRESP - Correspondence
2023/09/05

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/07/27

SEC问询函

Form CORRESP - Correspondence